Literature DB >> 19377085

The T-381C SNP in BNP gene may be modestly associated with type 2 diabetes: an updated meta-analysis in 49 279 subjects.

Hélène Choquet1, Christine Cavalcanti-Proença, Cécile Lecoeur, Christian Dina, Stéphane Cauchi, Martine Vaxillaire, Samy Hadjadj, Fritz Horber, Natasha Potoczna, Guillaume Charpentier, Juan Ruiz, Serge Hercberg, Suliya Maimaitiming, Ronan Roussel, Michael Boenhnke, Anne U Jackson, Wolfgang Patsch, Franz Krempler, Benjamin F Voight, David Altshuler, Leif Groop, Gudmar Thorleifsson, Valgerdur Steinthorsdottir, Kari Stefansson, Beverley Balkau, Philippe Froguel, David Meyre.   

Abstract

A recent study reported an association between the brain natriuretic peptide (BNP) promoter T-381C polymorphism (rs198389) and protection against type 2 diabetes (T2D). As replication in several studies is mandatory to confirm genetic results, we analyzed the T-381C polymorphism in seven independent case-control cohorts and in 291 T2D-enriched pedigrees totalling 39 557 subjects of European origin. A meta-analysis of the seven case-control studies (n = 39 040) showed a nominal protective effect [odds ratio (OR) = 0.86 (0.79-0.94), P = 0.0006] of the CC genotype on T2D risk, consistent with the previous study. By combining all available data (n = 49 279), we further confirmed a modest contribution of the BNP T-381C polymorphism for protection against T2D [OR = 0.86 (0.80-0.92), P = 1.4 x 10(-5)]. Potential confounders such as gender, age, obesity status or family history were tested in 4335 T2D and 4179 normoglycemic subjects and they had no influence on T2D risk. This study provides further evidence of a modest contribution of the BNP T-381C polymorphism in protection against T2D and illustrates the difficulty of unambiguously proving modest-sized associations even with large sample sizes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19377085     DOI: 10.1093/hmg/ddp169

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  18 in total

1.  Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes.

Authors:  Marica Bordicchia; Dianxin Liu; Ez-Zoubir Amri; Gerard Ailhaud; Paolo Dessì-Fulgheri; Chaoying Zhang; Nobuyuki Takahashi; Riccardo Sarzani; Sheila Collins
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

Review 2.  Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure.

Authors:  Chaitanya Madamanchi; Hassan Alhosaini; Arihiro Sumida; Marschall S Runge
Journal:  Int J Cardiol       Date:  2014-08-09       Impact factor: 4.164

3.  Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals.

Authors:  Susan Cheng; Caroline S Fox; Martin G Larson; Joseph M Massaro; Elizabeth L McCabe; Abigail May Khan; Daniel Levy; Udo Hoffmann; Christopher J O'Donnell; Karen K Miller; Christopher Newton-Cheh; Andrea D Coviello; Shalender Bhasin; Ramachandran S Vasan; Thomas J Wang
Journal:  Am J Cardiol       Date:  2011-08-01       Impact factor: 2.778

4.  Genome-wide association analysis of plasma B-type natriuretic peptide in blacks: the Jackson Heart Study.

Authors:  Solomon K Musani; Ervin R Fox; Aldi Kraja; Aurelian Bidulescu; Wolfgang Lieb; Honghuang Lin; Ashley Beecham; Ming-Huei Chen; Janine F Felix; Caroline S Fox; W H Linda Kao; Sharon L R Kardia; Ching-Ti Liu; Mike A Nalls; Tatjana Rundek; Ralph L Sacco; Jennifer Smith; Yan V Sun; Gregory Wilson; Zhaogong Zhang; Thomas H Mosley; Herman A Taylor; Ramachandran S Vasan
Journal:  Circ Cardiovasc Genet       Date:  2015-01-05

5.  A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community.

Authors:  Valentina Cannone; Guido Boerrigter; Alessandro Cataliotti; Lisa C Costello-Boerrigter; Timothy M Olson; Paul M McKie; Denise M Heublein; Brian D Lahr; Kent R Bailey; Maurizio Averna; Margaret M Redfield; Richard J Rodeheffer; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2011-08-02       Impact factor: 24.094

6.  Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies.

Authors:  Abigail May Khan; Susan Cheng; Martin Magnusson; Martin G Larson; Christopher Newton-Cheh; Elizabeth L McCabe; Andrea D Coviello; Jose C Florez; Caroline S Fox; Daniel Levy; Sander J Robins; Pankaj Arora; Shalender Bhasin; Carolyn S P Lam; Ramachandran S Vasan; Olle Melander; Thomas J Wang
Journal:  J Clin Endocrinol Metab       Date:  2011-08-17       Impact factor: 5.958

7.  Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.

Authors:  D E Adkins; K Aberg; J L McClay; J Bukszár; Z Zhao; P Jia; T S Stroup; D Perkins; J P McEvoy; J A Lieberman; P F Sullivan; E J C G van den Oord
Journal:  Mol Psychiatry       Date:  2010-03-02       Impact factor: 15.992

8.  Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women.

Authors:  Brendan M Everett; Nancy R Cook; Daniel I Chasman; Maria C Magnone; Maria Bobadilla; Nader Rifai; Paul M Ridker; Aruna D Pradhan
Journal:  Clin Chem       Date:  2013-01-03       Impact factor: 8.327

Review 9.  Pharmacogenomics of the Natriuretic Peptide System in Heart Failure.

Authors:  Ahmed Abuzaanona; David Lanfear
Journal:  Curr Heart Fail Rep       Date:  2017-12

Review 10.  Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.

Authors:  Sarah Mangiafico; Lisa C Costello-Boerrigter; Ingrid A Andersen; Alessandro Cataliotti; John C Burnett
Journal:  Eur Heart J       Date:  2012-08-31       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.